H Lee1, Y M Sohn2, J Y Ko2, S-Y Lee3, B W Jhun1, H Y Park1, K Jeon1, D H Kim1, S-Y Kim1, J E Choi4, I J Moon4, S J Shin5, H J Park2, W-J Koh1. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine. 2. Department of Pharmaceutical Services. 3. Department of Laboratory Medicine and Genetics. 4. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. 5. Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
Abstract
SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE: To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS: With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONCLUSION: Our results suggest that once-daily AMK for 4 weeks with a target Cmax of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.
SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE: To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS: With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONCLUSION: Our results suggest that once-daily AMK for 4 weeks with a target Cmax of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.
Authors: Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts Journal: Clin Pharmacokinet Date: 2021-05-13 Impact factor: 5.577
Authors: Maria Luisa Aznar; Theodore K Marras; Ahmed Said Elshal; Mahtab Mehrabi; Sarah K Brode Journal: BMC Pharmacol Toxicol Date: 2019-06-03 Impact factor: 2.483
Authors: Jacqueline M Ogier; Yujing Gao; Eileen M Dunne; Michael A Wilson; Sarath C Ranganathan; Gregory H Tesch; David J Nikolic Paterson; Alain Dabdoub; Rachel A Burt; Bryony A Nayagam; Paul J Lockhart Journal: J Mol Med (Berl) Date: 2022-04-26 Impact factor: 5.606